Edition:
United Kingdom

AnaptysBio Inc (ANAB.OQ)

ANAB.OQ on NASDAQ Stock Exchange Global Select Market

74.00USD
18 Apr 2019
Change (% chg)

$0.54 (+0.74%)
Prev Close
$73.46
Open
$73.48
Day's High
$74.13
Day's Low
$71.02
Volume
74,342
Avg. Vol
100,705
52-wk High
$110.00
52-wk Low
$54.38

Latest Key Developments (Source: Significant Developments)

Anaptysbio Reports Qtrly Loss Per Share Of $0.64
Thursday, 28 Feb 2019 

Feb 28 (Reuters) - AnaptysBio Inc ::ANAPTYSBIO ANNOUNCES FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES PIPELINE UPDATES.QTRLY LOSS PER SHARE $0.64.FOUR TOP-LINE PHASE 2 CLINICAL EFFICACY READOUTS FROM OUR WHOLLY-OWNED PIPELINE ANTICIPATED IN 2019.Q4 EARNINGS PER SHARE VIEW $-0.92 -- REFINITIV IBES DATA.EXPECTS THAT ITS CASH, CASH EQUIVALENTS AND INVESTMENTS WILL FUND ITS CURRENT OPERATING PLAN AT LEAST THROUGH END OF 2020.  Full Article

Anaptysbio Announces Pricing Of Public Offering Of Common Stock
Wednesday, 26 Sep 2018 

Sept 25 (Reuters) - AnaptysBio Inc ::ANAPTYSBIO ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 2.20 MILLION COMMON SHARES PRICED AT $94.46 PER SHARE.  Full Article

Anaptysbio Announces Proposed Public Offering Of Common Stock
Monday, 24 Sep 2018 

Sept 24 (Reuters) - AnaptysBio Inc ::ANAPTYSBIO ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.ANAPTYSBIO INC - INTENDS TO OFFER $200 MILLION OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.ANAPTYSBIO INC - INTENDS TO USE NET PROCEEDS FROM OFFERING TO FUND RESEARCH AND DEVELOPMENT ACTIVITIES FOR ITS CLINICAL DEVELOPMENT PROGRAMS.  Full Article

Anaptysbio Qtrly Loss Per Share $0.63
Tuesday, 8 May 2018 

May 8 (Reuters) - AnaptysBio Inc ::ANAPTYSBIO ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES PIPELINE UPDATES.ANAPTYSBIO INC - TOP-LINE PHASE 2A DATA FROM ANB020 IN EOSINOPHILIC ASTHMA EXPECTED IN Q3 OF 2018.ANAPTYSBIO INC - EXPECTS THAT ITS CASH, CASH EQUIVALENTS AND INVESTMENTS WILL FUND ITS CURRENT OPERATING PLAN THROUGH END OF 2019.ANAPTYSBIO INC QTRLY LOSS PER SHARE $0.63.  Full Article

Anaptysbio qtrly loss per share $0.45‍​
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Anaptysbio Inc ::Anaptysbio announces third quarter 2017 financial results and provides pipeline updates.Qtrly loss per share $0.45‍​.Q3 earnings per share view $-0.48 -- Thomson Reuters I/B/E/S.  Full Article

AnaptysBio reports positive ANB019 top-line phase 1 clinical trial results
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Anaptysbio Inc :Anaptysbio reports positive anb019 top-line phase 1 clinical trial results.Top-line data demonstrated favorable safety, pharmacokinetics and pharmacodynamic properties in study​.ANB019 was well-tolerated by all subjects and no dose-limiting toxicities were observed to date in study​.Plans to initiate phase 2 clinical trials of ANB019 in generalized pustular psoriasis, palmo-plantar pustular psoriasis patients in 2018​.  Full Article

Cormorant Asset Management reports 5.02 pct passive stake in Anaptysbio as of Oct. 19 ‍​
Friday, 20 Oct 2017 

Oct 20 (Reuters) - Cormorant Asset Management LLC: :Cormorant Asset Management, LLC reports 5.02 percent passive stake in Anaptysbio Inc as of October 19 - SEC filing ‍​.  Full Article

AnaptysBio prices public offering of 3 mln shares at $68.50 per share
Friday, 13 Oct 2017 

Oct 12 (Reuters) - AnaptysBio Inc -:AnaptysBio announces pricing of public offering.Says public offering of 3.00 million common shares priced at $68.50per share.  Full Article

Anaptysbio files for offering of 3 million shares
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Anaptysbio Inc :Anaptysbio files for offering of 3 million shares for up to $121.1 million – sec filing .  Full Article

AnaptysBio reports positive data from phase 2A clinical trial of ANB020 in atopic dermatitis
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - AnaptysBio Inc : :AnaptysBio reports positive topline proof-of-concept data from phase 2A clinical trial of ANB020 in atopic dermatitis.AnaptysBio Inc - ‍83 percent of patients achieved EASI-50 at day 29 following a single dose of ANB020​.AnaptysBio Inc - ‍ANB020 was generally well tolerated in all patients as of this interim analysis​.AnaptysBio-Continues to advance its ongoing ANB020 phase 2A studies in adults with severe peanut allergy with topline data expected in Q4 of 2017​.Anaptysbio Inc - ‍during first half of 2018, co plans to initiate a phase 2B randomized, double-blinded, placebo-controlled study​.AnaptysBio Inc - no severe adverse events have been reported to date on ‍ANB020 ​.AnaptysBio- also continues to advance ongoing ANB020 phase 2A studies in adults with severe eosinophilic asthma, topline data expected in first half of 2018​.  Full Article